Phosphate binder dose adjustment in chronic kidney disease
Phase 2
Completed
- Conditions
- Hyperphosphatemia and secondary hyperparathyroidism in children with chronic kidney disease stage III-VPhosphate binder, calcium carbonate, hyperphosphatemia, hyperparathyroidism, chronic kidney disease
- Registration Number
- TCTR20211119003
- Lead Sponsor
- Faculty of medicine, Siriraj hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Chronic kidney disease stage III-V
Calcium carbonate use as phosphate binder for at least 12 weeks
Exclusion Criteria
1.Calcium carbonate dosage adjustment in the past 12 weeks
2. Severe malnutrition
3.Serum calcium exceeding 11 mg/dL
4.Vitamin D deficiency
5.Use of calcium carbonate combined with other phosphate binder
6.Primary hyperparathyroidism
7.Acute kidney injury within the past 1 month
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hyperphosphatemia At the beginning and 12th week Serum phosphate
- Secondary Outcome Measures
Name Time Method Hyperparathyroidism At the beginning and 12th week Serum parathyroid hormone level